A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials.
A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials.
复制标题
DOI：
10.1038/sdata.2016.27
复制
发表时间：
2016-05-10
期刊：
影响因子：
9.8
通讯作者：
Butte AJ
中科院分区：
文献类型：
--
作者：
Geifman N;Butte AJ
开放的临床试验数据为科学界提供了许多机会，以独立验证已发表的结果，评估新的假设和进行荟萃分析。这些数据为医学研究的科学进步提供了宝贵的机会。在这里，我们提出了比较荟萃分析不同的标准治疗的治疗方法，从新获得的比较武器的数据，从几个前列腺癌的临床试验。比较米托蒽醌或多西他赛联合泼尼松以及单独泼尼松治疗后的生存率，验证了先前证明的多西他赛治疗的优效性。此外，在难治性前列腺癌中比较四种睾酮抑制治疗显示，接受手术去势的受试者的生存率显著低于接受LHRH、抗雄激素或LHRH+抗雄激素治疗的受试者，表明这种治疗选择不太理想。这项研究说明了如何使用患者水平的临床试验数据，使荟萃分析，可以提供新的见解标准的护理治疗的临床结果，因此，一旦验证，有可能帮助优化医疗保健服务。
Open clinical trial data offer many opportunities for the scientific community to independently verify published results, evaluate new hypotheses and conduct meta-analyses. These data provide valuable opportunities for scientific advances in medical research. Herein we present the comparative meta-analysis of different standard of care treatments from newly available comparator arm data from several prostate cancer clinical trials. Comparison of survival rates following treatment with mitoxantrone or docetaxel in combination with prednisone as well as prednisone alone, validated the previously demonstrated superiority of treatment with docetaxel. Additionally, comparison of four testosterone suppression treatments in hormone-refractory prostate cancer revealed that subjects who had undergone surgical castration had significantly lower survival rates than those treated with LHRH, anti-androgen or LHRH plus anti-androgen, suggesting that this treatment option is less optimal. This study illustrates how the use of patient-level clinical trial data enables meta-analyses that can provide new insights into clinical outcomes of standard of care treatments and thus, once validated, has the potential to help optimize healthcare delivery.